gmp-verlag.de
 

Never ever a 483?

We can not promise that you will never get a 483
but we know that the GMP MANUAL includes all 
procedures and processes you need to be
GMP compliant.
 
Stay informed!

If you’d like to be regularly informed of the latest developments at Good Manufacturing Practices

 

>>> simply register for our free GMP newsletter LOGFILE

 
 

Image

 
 
GMP Subject Downloads

BESTSELLER

1. GDP Audit Checklist
for the Storage and Transport of Pharmaceuticals

 

2. GMP Audit Checklist
for Pharmaceutical and API Manufacturers

 

3. Computer System Validation in the EU
a step-by-step guide to implementing a computer validation program

 

4. Risk Management
established methods of risk analysis
incl. ICH Q9

 

5. Preparing for the EU GMP Inspection
similarities - and subtle differences - between FDA and EU GMP inspections

 

Your benefits:

> no shipping costs
> no waiting period: if you choose payment by credit card you will receive an email with the download information immediately after payment.

 

>>> Click here to see all GMP Subject Downloads!

 

News about GMP/cGMP

Water for Injection (EDQM)

On April 1, 2010 European Pharmacopoeia Commission published information concerning a survey to possible changes regarding Water for Injection.

Currently, the European Pharmacopoeia only allows distillation for the production of Water for Injection (WFI). Renewed discussions have taken place at the end of 2009 amongst regulators in Europe on the suitability of using Reverse Osmosis (RO) to produce WFI. Concerns from regulators regarding the use of RO for the production of WFI had previously been expressed in a reflection paper issued by the Joint CHMP/CVMP Quality Working Party in early 2008.

 

Further to these discussions and to determine whether or not the problems/issues listed in this reflection paper are still valid, the European Pharmacopoeia Commission during its 135th session requested the EDQM to follow-up this issue. To this end, the EDQM has initiated a survey through industry associations to gather suitable information and data. The outcome of this survey and subsequent evaluation will further determine whether or not the monograph included in the European Pharmacopoeia dealing with WFI (Ph. Eur. 0169) should be amended to consider RO as a possible alternative. The list of points addressed in the survey is directly linked to those listed in the above mentioned reflection paper.

Outcome:

Return the  filled in survey and supportive data until May 30, 2010. Manufacturers are encouraged to channel their answers through the association they belong to.

Links:

EDQM/ Announcement

EMA/ Reflection Paper

Comments
No comment have jet been written about this news